Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
